NCT07128381 is a Phase 1, PHASE2 clinical trial of Axatilimab (SNDX-6352) in Myelofibrosis (MF), sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT07128381?

NCT07128381 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT07128381?

Interventions in NCT07128381: Axatilimab (SNDX-6352), Ruxolitinib.

What condition does NCT07128381 study?

NCT07128381 studies Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML).

Is NCT07128381 still recruiting?

NCT07128381 is currently recruiting now. Last updated 5 January 2026.

Last reviewed 2026-01-05 · How we verify

NCT07128381

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Recruiting now Phase 1, PHASE2 Last updated 5 January 2026

What this trial tests

Phase 1, PHASE2 trial testing Axatilimab (SNDX-6352) in Myelofibrosis (MF) in 66 participants. Currently enrolling.

Timeline

2 January 2026

Primary endpoint
31 July 2031

31 July 2033

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	66
Start date	2 January 2026
Primary completion	31 July 2031
Estimated completion	31 July 2033
Sites	1 location across United States

Drugs / interventions tested

Axatilimab (SNDX-6352) — full drug profile →
Ruxolitinib (RUXOLITINIB) — full drug profile →

Conditions studied

Myelofibrosis (MF) — all drugs for Myelofibrosis (MF) →
Chronic Myelomonocytic Leukemia (CMML) — all drugs for Chronic Myelomonocytic Leukemia (CMML) →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Myelofibrosis (MF) or Chronic Myelomonocytic Leukemia (CMML). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

* To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML. * To learn if axatilimab given in combination with ruxolitinib can help to control MF and CMML.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Axatilimab (SNDX-6352)

Trials testing the same drug.

NCT06959537 — A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifan · Phase 1 · recruiting

Other recruiting trials for Myelofibrosis (MF)

Currently open trials in the same condition.

NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting
NCT07419178 — A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemoki · NA · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07128381 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 5 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07128381.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing